WEST CHESTER, Pa. – May 9, 2016 – DePuy Orthopaedics, Inc., part of the DePuy Synthes Companies of Johnson & Johnson, announced today that it has acquired privately-held BioMedical Enterprises, Inc. (BME), a leading manufacturer of Nitinol orthopaedic implants for small bone fixation. The implants are used to treat bunions, hammertoes and other foot and ankle deformities, as well as hand and wrist deformities. The BME acquisition reinforces Johnson & Johnson Medical Devices focus on accelerating meaningful innovation and strengthening DePuy Synthes’ portfolio for elective extremity procedures - providing a more complete solution for foot and ankle and hand and wrist specialists.
BME is based in San Antonio, Texas and serves healthcare professionals in the United States and select markets throughout the world. BME, founded more than a decade ago, was one of the first U.S. manufacturers of Nitinol metal implants for musculoskeletal fixation and is a market leader in the use of memory metal implants for bone fixation. Nitinol is a nickel-titanium alloy that provides dynamic continuous active compression, which helps to promote healing after bone fixation. BME implants come ready-to-use on a sterilized, pre-loaded, fully disposable insertion tool.
“BME’s technology is an excellent complement to our comprehensive portfolio of solutions that spans all of orthopaedics,” said Ciro Römer, Company Group Chairman, DePuy Synthes. “The BME portfolio will be integrated into our trauma platform, where we will be able to expand the availability of these solutions, increase the pace of innovation in this area, and reach more patients around the world. We look forward to welcoming the BME employees to DePuy Synthes.”
DePuy Synthes is the global market leader in the foot and ankle and hand and wrist markets for bone fixation in trauma. The company’s implants and instruments are also used for the surgical treatment of orthopaedic deformities and tumor diseases.
About DePuy Synthes Companies
DePuy Synthes Companies of Johnson & Johnson provides the most comprehensive orthopaedic and neurological solutions in the world. The company offers an unparalleled breadth of products, services, programs and research and development capabilities. DePuy Synthes Companies’ solutions in the specialties of joint reconstruction, trauma, neurological, craniomaxillofacial, spinal surgery and sports medicine are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information visit,www.depuysynthes.com.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to the acquisition of Biomedical Enterprises, Inc (BME). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Orthopaedics, Inc, any of the other DePuy Synthes Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges related to integrating the products and employees of BME, as well as the ability to ensure continued performance or market growth of BME’s products; the potential that the expected benefits and opportunities related to the transaction may not be realized or may take longer to realize than expected; challenges inherent in product research and development, including the uncertainty of obtaining regulatory approvals; uncertainty of commercial success for new and existing products; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including global health care reforms; and changes in behavior and spending patterns or financial distress of purchasers of health care products and services. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov,www.jnj.com or on request from Johnson & Johnson. The DePuy Synthes Companies and Johnson & Johnson do not undertake to update any forward-looking statement as a result of new information or future events or developments.
###
©DePuy Synthes 2016. All rights reserved.
Contact:
Amber Hamilton
(212) 266-0062
Christie Corbett
(508) 977-2619
Jason Valmore
Investor Relations
(732) 524-3709